This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
by Zacks Equity Research
PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
Align Technology (ALGN) Gains on InvisAlign, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.
Omnicell's Higher Investments Drive Costs, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
by Zacks Equity Research
STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.
Integra Gains on Global Growth, Hurricanes Hamper Business
by Zacks Equity Research
Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.
Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid
by Zacks Equity Research
Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.
Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss
by Zacks Equity Research
Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.
Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down
by Zacks Equity Research
Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.